How has Jazz Pharmaceuticals's accrued development expenses changed year-over-year?

Jazz Pharmaceuticals's accrued development expenses decreased by 17.9% year-over-year, from $26.3M to $21.6M.

Jazz Pharmaceuticals JAZZ Accrued development expenses

Revenue$1.1B+19.1%

Operating income$336.6M+702%

Net income$293.1M+417%

EPS (diluted)$4.43+391%

Cash & equivalents$667.5M-64.1%

Total debt$5.4B-0.1%

Total equity$4.5B+8.6%

Total assets$11.9B+2.8%

Operating cash flow$408.2M-5.0%

CapEx$19.7M+41.7%

Free cash flow$388.5M-6.6%

Market cap$14.11B+54.4%

Enterprise value$18.85B+47.7%

P/S3.2×+0.9×

Operating margin-11.9%-28.1pp

Net margin-8.9%-20.5pp

FCF margin28.6%-8.6pp

Return on equity-9.1%-21.2pp

Debt / equity1.2×-0.1×

Current ratio2×-1.3×

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept jazz:AccruedDevelopmentExpensesCurrent.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Jazz Pharmaceuticals's accrued development expenses?: Jazz Pharmaceuticals (JAZZ) reported accrued development expenses of $21.6M in Q1 2026.
How has Jazz Pharmaceuticals's accrued development expenses changed year-over-year?: Jazz Pharmaceuticals's accrued development expenses decreased by 17.9% year-over-year, from $26.3M to $21.6M.